C22orf13 Inhibitors
The protein "guanylyl cyclase domain containing 1," abbreviated as GUCD1, is a member of the guanylyl cyclase family, which is known for its role in the production of cyclic guanosine monophosphate (cGMP) from guanosine triphosphate (GTP). GUCD1 is encoded by the GUCD1 gene.Guanylyl cyclases function as enzymes that catalyze the conversion of GTP to cGMP, an important second messenger in various physiological processes. cGMP acts as a signaling molecule within cells, playing a pivotal role in several signal transduction pathways. It is involved in the regulation of ion channels, certain protein kinases, and phosphodiesterases, influencing processes such as smooth muscle relaxation, phototransduction in the retina, and platelet aggregation.
The precise function of GUCD1 is not fully defined, but it is understood to contain a domain characteristic of guanylyl cyclases, suggesting a role in cGMP synthesis. The presence of this domain indicates that GUCD1 may be involved in cGMP-dependent signaling pathways, although the specifics of its substrate specificity, regulation, and tissue distribution may differ from other guanylyl cyclases.GUCD1 may be regulated by various physiological stimuli, including hormones, light, or changes in intracellular calcium levels. The activity of guanylyl cyclase proteins, in general, can be modulated by interacting proteins, ligand binding, or phosphorylation, which can alter their catalytic activity and, consequently, the levels of cGMP within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Similar to Sildenafil, Vardenafil is a PDE5 inhibitor and can indirectly influence GUCY1A3 activity by increasing cellular cGMP levels. | ||||||
Tadalafil | 171596-29-5 | sc-208412 | 50 mg | $180.00 | 13 | |
Another PDE5 inhibitor, Tadalafil, indirectly affects GUCY1A3 activity by enhancing cGMP levels due to reduced cGMP breakdown. | ||||||
ODQ | 41443-28-1 | sc-200325 sc-200325A | 10 mg 50 mg | $78.00 $222.00 | 13 | |
ODQ is an inhibitor of soluble guanylyl cyclase (sGC). While not specific to GUCY1A3, it can provide insights into the role of sGC in cellular processes. | ||||||
Methylene blue | 61-73-4 | sc-215381B sc-215381 sc-215381A | 25 g 100 g 500 g | $43.00 $104.00 $328.00 | 3 | |
Methylene Blue can act as a non-specific inhibitor of guanylyl cyclase, potentially affecting GUCY1A3-related pathways by reducing cGMP synthesis. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast, primarily a PDE5 inhibitor, can also inhibit PDE6 and PDE11, potentially affecting cGMP levels and indirectly influencing GUCY1A3 activity. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Dipyridamole is a phosphodiesterase inhibitor that increases cGMP levels by preventing its breakdown, indirectly affecting GUCY1A3 signaling pathways. | ||||||
Riociguat | 625115-55-1 | sc-476845 | 5 mg | $300.00 | ||
Riociguat sensitizes sGC to endogenous NO and directly stimulates sGC independently of NO. It can indirectly affect GUCY1A3 by modifying sGC activity and cGMP levels. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $109.00 $322.00 | 3 | |
Cilostazol inhibits phosphodiesterase 3 (PDE3) with resultant increases in cGMP (as well as cAMP), indirectly influencing the signaling pathways of GUCY1A3. | ||||||